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Simple Summary: Rapamycin is commonly used as an immunosuppressant, but also as an anti-aging
medicine. Despite its widespread use, results suggest that there is large variability in drug efficiency
among patients, and limited knowledge exists about potential side-effects. In the present study, we
investigated the effects of rapamycin using the common fruit fly as model organism. Six genetically
distinct lines were exposed to rapamycin, and the phenotypic consequence on fecundity, longevity
and heat stress tolerance was quantified. Flies exposed to rapamycin had increased longevity and
heat stress tolerance, however a side effect in the form of decreased fecundity was also observed. Our
data clearly show that the costs and benefits of rapamycin treatment is strongly genotype dependent.
These observations are important as they imply that a ‘one size fits all’ approach when it comes
to rapamycin treatment is not advisable. Future studies should address the underlying genetic
component that drive the drug response variability.
Abstract: Rapamycin is a powerful inhibitor of the TOR (Target of Rapamycin) pathway, which is an
evolutionarily conserved protein kinase, that plays a central role in plants and animals. Rapamycin
is used globally as an immunosuppressant and as an anti-aging medicine. Despite widespread use,
treatment efficiency varies considerably across patients, and little is known about potential side
effects. Here we seek to investigate the effects of rapamycin by using Drosophila melanogaster as
model system. Six isogenic D. melanogaster lines were assessed for their fecundity, male longevity
and male heat stress tolerance with or without rapamycin treatment. The results showed increased
longevity and heat stress tolerance for male flies treated with rapamycin. Conversely, the fecundity
of rapamycin-exposed individuals was lower than for flies from the non-treated group, suggesting
unwanted side effects of the drug in D. melanogaster. We found strong evidence for genotype-by-
treatment interactions suggesting that a ‘one size fits all’ approach when it comes to treatment
with rapamycin is not recommendable. The beneficial responses to rapamycin exposure for stress
tolerance and longevity are in agreement with previous findings, however, the unexpected effects
on reproduction are worrying and need further investigation and question common believes that
rapamycin constitutes a harmless drug.
Keywords: aging; fecundity; heat stress tolerance; Drosophila Genetic Reference Panel; rapamycin;
genotype by environment interaction; side effects
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1. Introduction
Development of new pharmaceuticals aimed to help humans suffering from conditions
requiring medical intervention is heavily commercialised. It is a multi-billion dollar
industry that has many stakeholders and large interests are at risk when new drugs are
developed, tested and made available on the market. The path from developing a new
drug, to obtain the permission to produce and finally to commercialise it, is long and
strongly controlled. However, sometimes, unwanted side effects, adverse interactions
with other drugs or genotype specific responses to a medical treatment can be hard to
detect when testing new drugs [1,2], and such unexpected and unwanted effects can lead
to recalling of already approved drugs [3].
Rapamycin and its analogue, everolimus, are approved for human use. They are
macrolide compounds, which have immunosuppressive properties. In mammals, ra-
pamycin acts as an allosteric inhibitor of TOR by binding to the protein FKBP12, which
inhibits the expression of TOR complex 1 [4]. The downstream processes of TOR complex 1
include the regulation of the initiation of protein synthesis, biogenesis of ribosomes, syn-
thesis of nucleic acids and autophagy [4,5]. Rapamycin has been proven effective against
lung cancer [4] and it is also effectively used for coating of coronary stents, prevention
of organ transplant rejection, and treatment of other lung diseases such as lymphangi-
oleiomyomatosis [6–8]. Further, numerous studies with model species, including yeast [9],
Drosophila [10–12] and mice [13–15], have revealed increased lifespan associated with
rapamycin intake. Aging is a major risk factor for a wide range of diseases, including
cardiovascular diseases, cancers, and neurodegenerative diseases, thus pharmacological
compounds that counteracts the effects of aging are of novel importance [16]. Rapamycin
constitutes an example of a drug that has been suggested to counteract many of the symp-
toms associated with age-related illnesses, such as Alzheimer’s disease, and reduced
cognitive abilities [4,17].
Individuals are genetically different and have experienced different environments
throughout life. This may severely impact on the responses to medical treatment and it
has been suggested, that 20–90% of the variation seen in the response to a medicine in
humans is attributable to genetic differences among patients [18]. Such knowledge is a
driver of the rapidly developing field of precision medicine [19]. However, in the process
of testing a new drug it is standard practice to investigate its efficiency and potential
unwanted side effects on one or few genetic backgrounds of cell cultures or laboratory
species. This provides limited possibility to investigate the impact of genetic background
on drug efficiency and genotype specific unwanted side effects. Therefore, small model
organism like Drosophila melanogaster, have been suggested as promising model system for
testing pharmacological interventions [20–23].
Here we tested the effect of rapamycin on six genetically different D. melanogaster lines
from the Drosophila Genetic Reference Panel (DGRP) [24,25]. The DGRP was established
from a wild caught out-crossed population from Raleigh, North Carolina, U.S.A. It consists
of 205 inbred lines each created though 20 generations of consecutive full sib mating. This
procedure produces isogenic lines where individuals within a line are genetically identical
(with an inbreeding coefficient of 1), which allows for testing numerus individuals with
the same genetic background from each line. Further, the different lines are genetically
diverged due to founder events and genetic drift. The DGRP has been assessed for nu-
merus traits and differ markedly in behavioural, morphological and life-history traits (see
Review by Mackay and Huang (2018) [26], and Anholt and Mackay (2018) [27]). Further,
lines from the DGRP have been shown to respond markedly different to drugs such as
methylamphetamine [28]. These characteristics of the DGRP system and the fact that all
lines are full genome sequenced make it an advantageous system for investigating the
genetic architecture of complex traits and genotype by environment interactions. Here we
fed individuals from six randomly selected DGRP lines with rapamycin or a control treat-
ment to investigate the impact of long-term rapamycin exposure (5–6 days or throughout
life for the longevity experiment) on male longevity and male heat stress tolerance, and
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on female fecundity. Overall, we find strong evidence for line-specific consequences of
rapamycin and unwanted side effects on fecundity. We also show that these finding are
not a consequence of genetic differences in the TOR gene but likely attributable to small
effects from a large number of genes; thus, response to rapamycin constitutes a complex
quantitative genetic trait.
2. Materials and Methods
2.1. D. melanogaster Husbandry
From the original set of 205 inbred D. melanogaster lines from the Drosophila Genetic
Reference Panel (DGRP) [24,25] a subset of six lines were randomly selected for the current
study (RAL-32, RAL-348, RAL-630, RAL-748, RAL-801 and RAL-819). The DGRP lines were
obtained from Bloomington Drosophila Stock Centre, and were kept at 23 ◦C under 12 h:12 h
light-dark cycles in vials with 7 mL standard oatmeal–sugar–yeast–agar D. melanogaster
medium [29] for two generations prior to the experiments. To produce experimental flies,
fly density was partly controlled by allowing approximately 15 individuals per vial to
reproduce for 24 h.
The individual flies used in this study were 24 ± 8 h old at the time of initiating
experiments. Flies were sorted by sex under light CO2 anaesthesia within 24 h after
emergence. Male flies were used for assessing longevity and heat stress tolerance whereas
both males and females were used for the fecundity experiment (File S1).
2.2. Life History and Stress Resistance Assays
Two life history and one stress resistance traits were investigated (fecundity, longevity
and heat stress tolerance), which are described in the sections below. Prior to each phe-
notypic assay the flies used were exposed to either a control treatment or the rapamycin
treatment. Rapamycin is insoluble in water; therefore, ethanol was added to both treatments
which consisted of 5% yeast extract, 5% sucrose, 50% demineralized water as well as 40%
ethanol. For the rapamycin treatment 200 µM rapamycin (99.3% purity, CAS: 53123-88-9,
Sigma Aldrich, Darmstadt, Germany) was added (this concentration was chosen based on
previous findings [11]). For all experiments, the solutions were fed to adult flies using the
capillary feeder (CAFÉ) assay [30]. In all experiments, the CAFÉ vials were kept within
closed containers with water at the bottom to maintain a high humidity to reduce evapora-
tion from the capillary tubes. The containers were kept in a climate chamber at 23 ◦C and
12 h:12 h light-dark cycle.
2.2.1. Heat Stress Tolerance
We quantified heat stress tolerance by assessing the upper thermal limit [31] of male
flies. For each DGRP line and treatment 60 males were distributed in six vials (ten per vial)
containing 3 mL 3% agar medium. The flies were exposed to either the control treatment or
the rapamycin treatment for five consecutive days using the CAFÉ assay. Hereafter, flies
from each treatment and DGRP line were pooled and a total of 25 flies were randomly
sampled per line and treatment. The flies were transferred to small empty glass vials
(15 × 45 mm Screw Neck Vial, 4 mL). Each vial contained one individual and was tightly
closed with a plastic screw cap. The vials were attached to a metal rack submerged in a
circulating thermostatically controlled water bath (Lauda LCK 1892, LCK1892-14-0006,
Lauda-Königshofen, Germany). The temperature of the water bath was increased with a
rate of 0.1 ◦C/min from an initial temperature of 23 ◦C. Flies were continuously monitored
and the temperature where no movement could be induced with a flashlight and a gentle
knocking on the vials with a stick was noted as the upper thermal limit (CTmax) [31].
2.2.2. Fecundity
The effect of rapamycin treatment on female-fecundity was measured by distributing
60 males and 60 females into four vials (i.e., 30 flies per vial) containing 3 mL 3% agar
medium for each DGRP line and treatment. The flies (both sexes) were exposed to either
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the control treatment or the rapamycin treatment for five consecutive days using the CAFÉ
assay. Agar medium without nutrients was used because we wanted flies to obtain nutrients
from the CAFÉ assay and not from standard nutritious Drosophila medium. Hereafter
25 pairs of one male and one female were transferred to individual vials containing 3 mL
3% agar medium with added black fruit colour to ease the quantification of eggs. Flies had
access to either the control treatment or the rapamycin treatment using the CAFÉ assay.
Every 24 h for three consecutive days the flies were transferred to new vials and capillary
tubes were exchanged with fresh solutions. Fecundity was estimated as the total number
of eggs laid per female across the three vials after three days.
2.2.3. Longevity
Longevity was quantified as the number of days individual male flies lived. 200 males
from each DGRP line and treatment were distributed equally in 20 vials containing 3 mL
3% agar medium, with access to either the control treatment or the rapamycin treatment
using the CAFÉ assay. Agar medium without nutrients was used because we wanted
flies to obtain nutrients from the CAFÉ assay and not from standard nutritious Drosophila
medium. Once per day, dead flies in each vial were counted and removed. In this process
capillary tubes were exchanged with fresh solutions. The flies were transferred to new
vials with fresh agar once per week.
2.3. Statistical Analysis
All statistical analyses were performed in R (v. 4.2) [32]. For heat stress tolerance and
fecundity we assessed the effect of rapamycin using a linear mixed model as implemented
in the R package ‘lme4′ [33]. To approximate a Gaussian distribution the data were rank
normalized. We fitted the model
y = g + t + g × t + e, (1)
where y was the rank normalized heat stress tolerance quantity or fecundity measurement,
t was the fixed effect of treatment, g was a random DGRP line effect, g × t was a random
genotype-by-treatment interaction effect, and e was the remaining residual. Statistical
differences within DGRP genotypes between treatments was determined using Welch Two
Sample t-test. The longevity data was analysed using a survival model implemented in the
‘survival’ package [34]. The data were visualised with Kaplan–Meier curves, and statistical
difference in survival curves between treatment groups was assessed using the log-rank test.
3. Results
The aim of the current study was to investigate the effect of rapamycin treatment on
three fitness components: the upper thermal limit (CTmax) in males, fecundity (number
of eggs mated females produced) and male longevity. The DGRP-line average for CTmax
of flies exposed to the control treatment ranged from 38.4–40.0 ◦C, whereas the range of
values for flies exposed to rapamycin was 39.6–40.2 ◦C (Figure 1A). We found a strong
and significant genotype-by-treatment interaction (p-value = 9.4× 10−9), and a significant
overall treatment effect (p-value = 0.031). Treatment with rapamycin significantly increased
CTmax in four of the six DGRP lines investigated (Figure 1B), and interestingly, the range of
CTmax values for the rapamycin treated flies were much narrower than the CTmax of the
control flies.
Rapamycin treatment significantly lowered the number of eggs produced (Figure 2A,
p-value = 0.007). Similar to the observation for heat stress tolerance, we also observed
a strong genotype-by-treatment interaction effect for fecundity (p-value = 0.0003). The
number of eggs produced by the control treated DGRP lines ranged from 15 eggs to an
average of 0.8 eggs, and with rapamycin treatment this was lowered to 5.1–0.05 eggs
(Figure 2A). Fecundity was significantly reduced in the rapamycin treated group for four
of the six DGRP lines (Figure 2B).
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i lif s a of the control-treated male flies was between 28.5 days and
53.0 days, and with rapamycin treatment this range was betw en 38.0 days an . .
h s, hile the lo er average lifespan as increased arkedly by rapa ycin treat ent
t e upper lifespan was not. Only for two of the six DGRP lines investigated, we observed a
significantly increased longevity with rap mycin treatment (Figure 3).
T e response to rapamycin-treatment (i.e., the phenotypic difference within line mean
values between control treatment a d rapamycin treatment) was strongl correlated with
basal trait values (i.e., within line mea tr it values) (Figure 4). The DGRP lines that were
most heat tolerant (i.e., highest CTmax) when exposed to the control treatment (basal level)
responded little to rapamycin treatment for this trait wh reas those lines that h d the lowest
basal CTmax responded strongly to rapamyci in the form of i creased CTmax (Figure 4A).
Likewise for longevity wher lines that had low basal longevity res onded most in the
form of increased longevity when exp sed to rapamycin (Figure 4C). For fecundity we
observed that the lin s with h ghest basal fecundity experienced the most pronounced
decrease in fecundity when treated with rapamycin (Figure 4B). In combination, our results
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unambiguously illustrate that the phenotypic consequences of treating D. melanogaster with
rapamycin is highly genotype specific (Figure 5) and further that the directional effect is
trait specific.




Figure 3. Kaplan–Meier plots of male D. melanogaster longevity within DGRP lines for flies exposed 
to the control treatment (black line) or the rapamycin treatment (grey line). p-values are from log-
rank test. 
The response to rapamycin-treatment (i.e., the phenotypic difference within line 
mean values between control treatment and rapamycin treatment) was strongly corre-
lated with basal trait values (i.e., within line mean trait values) (Figure 4). The DGRP lines 
that were most heat tolerant (i.e., highest CTmax) when exposed to the control treatment 
(basal level) responded little to rapamycin treatment for this trait whereas those lines that 
had the lowest basal CTmax responded strongly to rapamycin in the form of increased CTmax 
(Figure 4A). Likewise for longevity where lines that had low basal longevity responded 
most in the form of increased longevity when exposed to rapamycin (Figure 4C). For fe-
cundity we observed that the lines with highest basal fecundity experienced the most pro-
nounced decrease in fecundity when treated with rapamycin (Figure 4B). In combination, 
our results unambiguously illustrate that the phenotypic consequences of treating D. mel-
anogaster with rapamycin is highly genotype specific (Figure 5) and further that the direc-
tional effect is trait specific. 
 
(A) (B) (C) 
Figure 4. Trait-correlations between basal trait level (control treatment) and the phenotypic re-
sponse to treatment (expressed as ycontrol-yrapamycin, where y represent one of the three phenotypes) 
for CTmax (A), fecundity (B) and longevity (C). Results are based on the within treatment line means. 
Spearman’s rank correlation coefficients (𝜌) with corresponding significance levels are shown for 
each trait. Numbers above each point are the DGRP line IDs. 


















P val =  0.33
32


















P val =  0.0042
348


















P val =  0.92
630


















P val =  0.26
748


















P val =  0.0012
801






















Figure 3. Kaplan–Meier plots of male D. melanogaster longevity within DGRP lines for flies exposed to
the control treatment (black line) or the rapamycin treatment (grey line). p-values are from log-rank test.




Figure 3. Kaplan–Meier plots of male D. melanogaster longevity within DGRP lines for flies exposed 
to the control treatment (black line) or the rapamycin treatment (grey line). p-values are from log-
rank test. 
The response to rapamycin-treatment (i.e., the phenotypic difference within line 
mean values between control treatment and rapamycin treatment) was strongly corre-
lated with basal trait values (i.e., within line mean trait values) (Figure 4). The DGRP lines 
that were most heat tolerant (i.e., highest CTmax) when exposed to the control treatment 
(basal level) responded little to rapamycin treatment for this trait whereas those lines that 
had the lowest basal CTmax responded strongly to rapamycin in the form of increased CTmax 
(Figure 4A). Likewise for longevity where lines that had low basal longevity responded 
most in the form of increased longevity when exposed to rapamycin (Figure 4C). For fe-
cundity we observed that the lines with highest basal fecundity experienced the most pro-
nounced decrease in fecundity when treated with rapamycin (Figure 4B). In combination, 
our results unambiguously illustrate that the phenotypic consequences of treating D. mel-
anogaster with rapamycin is highly genotype specific (Figure 5) and further that the direc-
tional effect is trait specific. 
 
(A) (B) (C) 
Figure 4. Trait-correlations between basal trait lev l (control t atme t) and the phenotyp c re-
sponse to treatmen (expressed as ycontrol-yrapamycin, where y represent one of the three phenotypes) 
for CTmax (A), fecundity (B) and longevity (C). Results are based on the within treatment line means. 
Spearman’s rank correlation coefficients (𝜌) with corresponding significance levels are shown for 
each trait. Numbers above each point are the DGRP line IDs. 


















P val =  0.33
32


















P val =  0.0042
348


















P val =  0.92
630


















P val =  0.26
748


















P val =  0.0012
801






















Figure 4. Trait-correlations between basal trait level (control treatment) and the phenotypic response
to treatment (expressed as ycontrol-yrapamycin, where y represent on of the thre phenotypes) for
CTmax (A), fecundity (B) and longevity (C). Results are based o the within treatment line means.
Spearman’s rank correlation coefficients (ρ) with corresponding significance levels are shown for
each trait. Numbers above each point are the DGRP line IDs.




Figure 5. Result overview of significant within DGRP-line treatment effects (DGRP line ID is 
shown to the right on the figure). 
4. Discussion 
The main aim of this study was to investigate the effect of rapamycin on fecundity, 
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4. Discussion
The main aim of this study was to investigate the effect of rapamycin on fecundity,
heat tolerance, and longevity, and further if responses to rapamycin differed between lines
that were genetically distinct. Using the DGRP lines for this purpose provide benefits
because individuals from a given line are genome-wide homozygous meaning that a large
number of genetically identical individuals can be tested across and within different treat-
ments [24,25]. The DGRP system has been widely used to investigate the genetic basis of
complex traits [26,27], and genotype by treatment interactions [28,35–37], however, this is
to our knowledge the first study using the DGRP system to investigate rapamycin intake.
In accordance with previous findings from D. melanogaster we see a reduction of fecundity
estimated by the number of eggs produced over a 72 h time period in flies exposed to
rapamycin (Figure 2) [11,12]. Furthermore, we found that the impacts of rapamycin on
fecundity was highly line specific with four of the six lines having significantly reduced
fecundity whereas no effect of rapamycin treatment was observed for two lines (Figure 2).
We are not aware of studies on other species revealing these unwanted side effects of
rapamycin on traits related to reproduction. In contrast, mTOR modulators including ra-
pamycin has been suggested to ameliorate fertility issues in e.g., humans and mice [38,39].
For example, Dou et al. (2017) [39] showed that rapamycin treatment of mice can in-
crease ovarian lifespan providing a potential tool to delay menopause. Moreover, when
it comes to fertility-related diseases in humans including polycystic ovarian syndrome
and endometriosis, rapamycin can have positive effects [38]. Thus, the finding that D.
melanogaster produces less eggs when treated with rapamycin is somewhat contrary to
findings in mammals illustrating the need for further studies on the impact of rapamycin
on traits related to fertility and fecundity. In the interpretation of our fecundity data, it
should however be kept in mind that our design does not allow for distinguishing between
reduced fecundity and delayed fecundity. We assessed fecundity of females in a 72-h
window early in life when flies were 5 to 8 days old. In this time-period the rapamycin
treated flies had lower fecundity in four of the six lines. Since manipulation of TOR can
affect developmental speed [40], some lines may have reduced fecundity early in life but
increased fecundity at later ages. Longevity-fertility trade-offs is a common observation in
studying life-history traits [11,41], thus lifelong fecundity should preferably be investigated
in future studies on the effect of rapamycin on fecundity and longevity.
The heat stress tolerance assessed in a temperature-ramping assay in our study re-
vealed that CTmax was significantly higher in male flies that had been exposed to rapamycin
in four out of the six lines (Figure 1). Bjedov et al. (2010) [11] studied starvation resistance
and found that both male and female D. melanogaster fed with rapamycin had an increased
tolerance. These results suggest that rapamycin treatment in D. melanogaster increases
robustness towards multiple environmental stresses. Chou et al. (2012) [42] found that the
inhibition of mTOR results in a reduced production of heat shock proteins (Hsp). Based
on the knowledge that Hsp are important for coping with high temperature stress [43,44]
flies treated with rapamycin would then be expected to have reduced CTmax which is
opposite to what we see. However, Duncan (2008) [45] found that while rapamycin blocks
the translation of Hsp90, it does not affect the translation of Hsp70; thus not all Hsps are
inhibited by rapamycin. Our study does not provide an explanation for why rapamycin
causes increased heat tolerance in male flies but the involvement of TOR in several stress
resistance pathways across a range of species is well known [46,47]. Interestingly, the
positive impact of rapamycin on CTmax is not a universal finding across the investigated
lines again showing strong impact of genotype on response to rapamycin in this trait. It is
well known that the ability to cope with environmental stress including heat tolerance in
D. melanogaster degreases with age [48–51]. Given that rapamycin treatment has anti-aging
properties we suggest that the finding of increased heat tolerance in flies feed rapamycin is
linked to a younger physiological age of these flies at the time of testing their CTmax (flies
ca. 6 days old). This hypothesis needs experimental testing, and our data does not allow
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for investigating whether the finding of higher CTmax in rapamycin treated flies is linked
to altered expression of Hsps in consequence of TOR inhibition.
Our longevity data confirmed previous findings from multiple species showing that
rapamycin treatment has life-extending properties [46]. Bjedov et al. (2010) [11], Emran
et al. (2014) [12], and Wang et al. (2016) [52] also found that rapamycin treatment of D.
melanogaster with rapamycin significantly increased lifespan. Fok et al. (2014) [14] also
found an 11% increase in the lifespan of male mice, using a corresponding concentration
of 15.31 µM. Conversely, other Drosophila studies have demonstrated that treatment with
rapamycin may shorten lifespan under certain drug dosages [53] or under nutritional
stress [54]. In contrast to previous studies, we investigated impacts of rapamycin on several
genetic backgrounds allowing for the investigation of genotype specific responses. As for
the other traits assessed, longevity was also impacted in a highly line specific manner by
rapamycin as only lines 348 and 801 had significantly increased longevity when treated
with the drug (Figure 3). Interesting the median upper lifespan did not differ markedly
between control and rapamycin treated flies (53.0 and 55.0 days, respectively) while the
median lower lifespan was much higher for the flies exposed to rapamycin (28.5 and 38.0
days, respectively). This suggests that the upper lifespan limit is more constrained than the
lower limit, which have also been suggested to be the case in humans [55].
We cannot rule out the lifespan of the flies and the phenotypic values for other traits
investigated have been affected by the high ethanol concentration in the feed. Chan-
dler et al. (2018) [56] investigated the effect of consumed ethanol on the lifespan of D.
melanogaster with a maximum concentration of 15% and discovered a 15% reduction in
lifespan. However, average male lifespan of the six DPRP lines investigated here does
not deviate from estimates in the literature [57,58] and ethanol concentrations in natural
Drosophila habitats (decomposing fruit) can be high [59]. This combined with the fact that
both our experimental treatments had the same ethanol concentration suggest that this is
not a big issue for interpretation of results from the current study.
Our experiment showed that treatment with 200 µM rapamycin significantly increased
longevity and heat stress tolerance in male D. melanogaster. In contrast, fecundity was
reduced in the rapamycin treated flies. For all traits we observed strong genotype by
treatment interactions. Interestingly, we also found that for heat tolerance and longevity
lines with high basal trait values for these traits responded little to rapamycin treatment
whereas poor performing lines benefit more from rapamycin treatment (Figure 4A,C). We
also observed that lines with high basal fecundity experienced the strongest cost in terms
of reduced fecundity when treated with rapamycin (Figure 4B). Similar findings showing
plastic responses to environmental changes being associated with basal trait levels have
been reported for responses to thermal acclimation [60]. These results suggest an upper
limit to performance that is hard to break by rapamycin and therefore the potential of
rapamycin treatment seem larger for individuals with low fitness.
Our results have several implications: (1) when assessing effects of a medical drug
multiple genetic backgrounds should be investigated because effects are typically genotype-
specific, (2) several traits should be investigated because the effects of the medication is trait
specific, (3) effects of rapamycin are not only genotype specific, but the genotype specificity
is trait-specific (Figure 5) and (4) trait values of a given line (genotype) to a large extent
predict costs and benefits of rapamycin exposure suggesting e.g., that positive effects of
rapamycin is likely to be observed mainly in individuals with low fitness. Altogether these
findings add to the complexity of medication exposure in general and rapamycin treatment
specifically and warrant against conclusions based on testing one genetic background
and one phenotype. Additionally, sex specific responses, which are not investigated in
this study, should be further investigated. The strong genotype by treatment interactions
observed here, and in another recent study on Ritalin treatment using the DGRP lines [28]
also highlight the need and potential for tailoring treatment to the individual patient
guided by the genetic profile.
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The aim of this study was to investigate genotype specific responses to rapamycin
and if unwanted side-effects of rapamycin was observed. Due to power limitations (with
only six lines investigated) we were not able to perform a genome-wide association study
investigating the genetic architecture of response to rapamycin treatment. However, we
did look into whether the drug response variability observed in our study was driven
by genetic differences within the gene encoding TOR. Using the genome-wide available
genotypes [24,25] we extracted the TOR-gene, and by using Variant Effect Predictor [61]
the protein effect was predicted. By doing that we observed a total of 102 genetic variants
within TOR, whereof 20 were located in intron regions, 75 were synonymous variants,
five variants were located in UTR ‘3 and two were predicted to be missense variants.
Thus, only the two missense variants are of interest, as these causes changes in the amino
acid sequence of the protein. However, those two variants were not segregating among
the six randomly chosen DGRP lines, and therefore we cannot assess the important of
genetic variation within TOR for rapamycin response. Hence, the observed line-specific
responses to rapamycin is not due to genetic variation within the TOR gene, but is likely
caused by small effect variants distributed across many loci, which is consistent with the
perception that drug-response phenotypes constitute complex quantitative genetic traits
(as demonstrated by several DGRP studies [28,35,62,63]. Future studies using the DGRP
can be useful for pinpointing the genetic architecture of rapamycin response and reveal
putative genes responsible for the reaction to rapamycin treatment. We also advocate that
future studies investigating rapamycin in DGRP lines obtain baseline levels of TOR activity
as well as after exposure to rapamycin, in particular as previous study has demonstrated
that flies exposed to rapamycin display reduced TOR activity [11]. This would allow for
deeper insight into the mechanistic basis of our findings.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/insects12050474/s1, File S1: Data.
Author Contributions: Conceptualization, T.N.K.; formal analysis, P.D.R.; investigation, A.B.,
C.A.B.J., A.L.B., M.I.J.M., S.L.C. and S.B.V.; writing—original draft preparation, T.N.K., P.D.R., A.B.
and C.A.B.J.; visualization, P.D.R.; supervision, T.N.K., P.D.R.; project administration, T.N.K.; funding
acquisition, T.N.K. All authors have read and agreed to the published version of the manuscript.
Funding: The study was supported by the Danish Natural Science Research Council through a grant
to TNK (DFF-8021-00014B).
Institutional Review Board Statement: Not applicable.
Data Availability Statement: Available in supplementary material.
Acknowledgments: The DGRP lines used in the current study were obtained from the Bloomington
Drosophila Stock Center (NIH P40OD018537).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Rohani, N.; Eslahchi, C. Drug-drug interaction predicting by neural network using integrated similarity. Sci. Rep. 2019, 9, 1–11.
[CrossRef] [PubMed]
2. Malki, M.A.; Pearson, E.R. Drug–drug–gene interactions and adverse drug reactions. Pharm. J. 2020, 20, 355–366. [CrossRef]
3. Veeren, J.C.; Weiss, M. Trends in emergency hospital admissions in England due to adverse drug reactions: 2008–2015. J. Pharm.
Health Serv. Res. 2017, 8, 5–11. [CrossRef]
4. Li, J.; Kim, S.G.; Blenis, J. Rapamycin: One drug, many effects. Cell Metab. 2014, 19, 373–379. [CrossRef] [PubMed]
5. Ma, X.M.; Blenis, J. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 2009, 10, 307–318.
[CrossRef]
6. Saunders, R.N.; Metcalfe, M.S.; Nicholson, M.L. Rapamycin in transplantation: A review of the evidence. Kidney Int. 2001, 59,
3–16. [CrossRef]
7. Serruys, P.W.; Regar, E.; Carter, A.J. Rapamycin eluting stent: The onset of a new era in interventional cardiology. Heart 2002, 87,
305–307. [CrossRef]
8. Kennedy, B.K.; Pennypacker, J.K. Mammalian target of rapamycin: A target for (lung) diseases and aging. Ann. Am. Thorac. Soc.
2016, 13, S398–S401. [CrossRef]
Insects 2021, 12, 474 10 of 11
9. Kaeberlein, M. Resveratrol and rapamycin: Are they anti-aging drugs? BioEssays 2010, 32, 96–99. [CrossRef]
10. Kapahi, P.; Zid, B.M.; Harper, T.; Koslover, D.; Sapin, V.; Benzer, S. Regulation of lifespan in Drosophila by modulation of genes in
the TOR signaling pathway. Curr. Biol. 2004, 14, 1–6. [CrossRef]
11. Bjedov, I.; Toivonen, J.M.; Kerr, F.; Slack, C.; Jacobson, J.; Foley, A.; Partridge, L. Mechanisms of life span extension by rapamycin
in the fruit fly Drosophila melanogaster. Cell Metab. 2010, 11, 35–46. [CrossRef] [PubMed]
12. Emran, S.; Yang, M.; He, X.; Zandveld, J.; Piper, M.D.W. Target of rapamycin signalling mediates the lifespan-extending effects of
dietary restriction by essential amino acid alteration. Aging 2014, 6, 390–398. [CrossRef] [PubMed]
13. Harrison, D.E.; Strong, R.; Sharp, Z.D.; Nelson, J.F.; Astle, C.M.; Flurkey, K.; Nadon, N.L.; Wilkinson, J.E.; Frenkel, K.; Carter,
C.S.; et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460, 392–395. [CrossRef]
[PubMed]
14. Fok, W.C.; Chen, Y.; Bokov, A.; Zhang, Y.; Salmon, A.B.; Diaz, V.; Javors, M.; Wood, W.H.; Zhang, Y.; Becker, K.G.; et al. Mice fed
rapamycin have an increase in lifespan associated with major changes in the liver transcriptome. PLoS ONE 2014, 9. [CrossRef]
15. Wilkinson, J.E.; Burmeister, L.; Brooks, S.V.; Chan, C.C.; Friedline, S.; Harrison, D.E.; Hejtmancik, J.F.; Nadon, N.; Strong, R.;
Wood, L.K.; et al. Rapamycin slows aging in mice. Aging Cell 2012, 11, 675–682. [CrossRef]
16. Ehninger, D.; Neff, F.; Xie, K. Longevity, aging and rapamycin. Cell. Mol. Life Sci. 2014, 71, 4325–4346. [CrossRef]
17. Johnson, S.C.; Rabinovitch, P.S.; Kaeberlein, M. MTOR is a key modulator of ageing and age-related disease. Nature 2013, 493,
338–345. [CrossRef]
18. Evans, W.E.; Mcleod, H.L. Pharmacogenomics—drug disposition, drug targets, and side effects. N. Engl. J. Med. 2003, 348,
538–549. [CrossRef]
19. Rohde, P.D.; Kristensen, T.N. Untangling the genetic basis of drug response. Pharmacogenomics 2020, 21, 87–89. [CrossRef]
20. Lee, S.H.; Min, K.J. Drosophila melanogaster as a model system in the study of pharmacological interventions in aging. Transl. Med.
Aging 2019, 3, 98–103. [CrossRef]
21. Su, T.T. Drug screening in Drosophila; why, when, and when not? WIREs Dev. Biol. 2019, 8, e346. [CrossRef] [PubMed]
22. Jafari, M.; Long, A.D.; Mueller, L.D.; Rose, M.R. The pharmacology of ageing in Drosophila. Curr. Drug Targets 2006, 7, 1479–1483.
[CrossRef] [PubMed]
23. Pandey, U.B.; Nichols, C.D. Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery.
Pharmacol. Rev. 2011, 63, 411–436. [CrossRef] [PubMed]
24. Huang, W.; Massouras, A.; Inoue, Y.; Peiffer, J.; Ràmia, M.; Tarone, A.M.; Turlapati, L.; Zichner, T.; Zhu, D.; Lyman, R.F.; et al.
Natural variation in genome architecture among 205 Drosophila melanogaster Genetic Reference Panel lines. Genome Res. 2014, 24,
1193–1208. [CrossRef] [PubMed]
25. Mackay, T.F.C.; Richards, S.; Stone, E.A.; Barbadilla, A.; Ayroles, J.F.; Zhu, D.; Casillas, S.; Han, Y.; Magwire, M.M.; Cridland, J.M.;
et al. The Drosophila melanogaster Genetic Reference Panel. Nature 2012, 482, 173–178. [CrossRef]
26. Mackay, T.F.C.; Huang, W. Charting the genotype–phenotype map: Lessons from the Drosophila melanogaster Genetic Reference
Panel. Wiley Interdiscip. Rev. Dev. Biol. 2018, 7, 1–18. [CrossRef]
27. Anholt, R.R.H.; Mackay, T.F.C. The road less traveled: From genotype to phenotype in flies and humans. Mamm. Genome 2018, 29,
5–23. [CrossRef]
28. Rohde, P.D.; Jensen, I.R.; Sarup, P.M.; Ørsted, M.; Demontis, D.; Sørensen, P.; Kristensen, T.N. Genetic signatures of drug response
variability in Drosophila melanogaster. Genetics 2019, 213, 633–650. [CrossRef]
29. Kristensen, T.N.; Henningsen, A.K.; Aastrup, C.; Bech-Hansen, M.; Bjerre, L.B.H.; Carlsen, B.; Hagstrup, M.; Jensen, S.G.; Karlsen,
P.; Kristensen, L.; et al. Fitness components of Drosophila melanogaster developed on a standard laboratory diet or a typical natural
food source. Insect Sci. 2016, 23, 771–779. [CrossRef]
30. Ja, W.W.; Carvalho, G.B.; Mak, E.M.; De La Rosa, N.N.; Fang, A.Y.; Liong, J.C.; Brummel, T.; Benzer, S. Prandiology of Drosophila
and the CAFE assay. Proc. Natl. Acad. Sci. USA 2007, 104, 8253–8256. [CrossRef]
31. Overgaard, J.; Kristensen, T.N.; Sørensen, J.G. Validity of thermal ramping assays used to assess thermal tolerance in arthropods.
PLoS ONE 2012, 7, 1–7. [CrossRef] [PubMed]
32. R Core Team R. A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2020.
33. Bates, D.; Mächler, M.; Bolker, B.M.; Walker, S.C. Fitting linear mixed-effects models using lme4. J. Stat. Softw. 2015, 67, 1–48.
[CrossRef]
34. Therneau, T.M.; Grambsch, P.M. Modeling Survival Data: Extending the Cox Model; Springer: Berlin/Heidelberg, Germany, 2000;
ISBN 0-387-98784-3.
35. Fochler, S.; Morozova, T.V.; Davis, M.R.; Gearhart, A.W.; Huang, W.; Mackay, T.F.C.; Anholt, R.R.H. Genetics of alcohol
consumption in Drosophila melanogaster. Genes Brain Behav. 2017, 16, 675–685. [CrossRef] [PubMed]
36. Battlay, P.; Schmidt, J.M.; Fournier-Level, A.; Robin, C. Genomic and transcriptomic associations identify a new insecticide
resistance phenotype for the selective sweep at the Cyp6g1 locus of Drosophila melanogaster. G3 Genes Genomes Genet. 2016, 6,
2573–2581. [CrossRef]
37. Montgomery, S.L.; Vorojeikina, D.; Huang, W.; Mackay, T.F.C.; Anholt, R.R.H.; Rand, M.D. Genome-wide association analysis of
tolerance to methylmercury toxicity in Drosophila implicates myogenic and neuromuscular developmental pathways. PLoS ONE
2014, 9, e110375. [CrossRef]
38. Guo, Z.; Yu, Q. Role of mTOR signaling in female reproduction. Front. Endocrinol. 2019, 10, 1–13. [CrossRef]
Insects 2021, 12, 474 11 of 11
39. Dou, X.; Sun, Y.; Li, J.; Zhang, J.; Hao, D.; Liu, W.; Wu, R.; Kong, F.; Peng, X.; Li, J. Short-term rapamycin treatment increases
ovarian lifespan in young and middle-aged female mice. Aging Cell 2017, 16, 825–836. [CrossRef]
40. Potter, S.; Sifers, J.; Yocom, E.; Blümich, S.L.E.; Potter, R.; Nadolski, J.; Harrison, D.A.; Cooper, R.L. Effects of inhibiting mTOR with
rapamycin on behavior, development, neuromuscular physiology and cardiac function in larval Drosophila. Biol. Open 2019, 8.
[CrossRef] [PubMed]
41. Carey, J.R.; Harshman, L.G.; Liedo, P.; Müller, H.G.; Wang, J.L.; Zhang, Z. Longevity-fertility trade-offs in the tephritid fruit fly,
Anastrepha ludens, across dietary-restriction gradients. Aging Cell 2008, 7, 470–477. [CrossRef]
42. Chou, S.D.; Prince, T.; Gong, J.; Calderwood, S.K. mTOR is essential for the proteotoxic stress response, HSF1 activation and heat
shock protein synthesis. PLoS ONE 2012, 7, 1–9. [CrossRef]
43. Sørensen, J.G.; Kristensen, T.N.; Loeschcke, V. The evolutionary and ecological role of heat shock proteins. Ecol. Lett. 2003, 6,
1025–1037. [CrossRef]
44. Sørensen, J.G.; Loeschcke, V.; Kristensen, T.N. Lessons from the use of genetically modified Drosophila melanogaster in ecological
studies: Hsf mutant lines show highly trait-specific performance in field and laboratory thermal assays. Funct. Ecol. 2009, 23,
240–247. [CrossRef]
45. Duncan, R.F. Rapamycin conditionally inhibits Hsp90 but not Hsp70 mRNA translation in Drosophila: Implications for the
mechanisms of Hsp mRNA translation. Cell Stress Chaperones 2008, 13, 143–155. [CrossRef] [PubMed]
46. Welch, A.Z.; Gibney, P.A.; Botstein, D.; Koshland, D.E. TOR and RAS pathways regulate desiccation tolerance in Saccharomyces
cerevisiae. Mol. Biol. Cell 2013, 24, 115–128. [CrossRef] [PubMed]
47. Yoshihara, T.; Naito, H.; Kakigi, R.; Ichinoseki-Sekine, N.; Ogura, Y.; Sugiura, T.; Katamoto, S. Heat stress activates the Akt/mTOR
signalling pathway in rat skeletal muscle. Acta Physiol. 2013, 207, 416–426. [CrossRef] [PubMed]
48. Colinet, H.; Chertemps, T.; Boulogne, I.; Siaussat, D. Age-related decline of abiotic stress tolerance in young drosophila
melanogaster adults. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 2016, 71, 1574–1580. [CrossRef] [PubMed]
49. Vermeulen, C.J.; Loeschcke, V. Longevity and the stress response in Drosophila. Exp. Gerontol. 2007, 42, 153–159. [CrossRef]
50. Kristensen, T.N.; Loeschcke, V.; Tan, Q.; Pertoldi, C.; Mengel-From, J. Sex and age specific reduction in stress resistance and
mitochondrial DNA copy number in Drosophila melanogaster. Sci. Rep. 2019, 9, 1–7. [CrossRef]
51. Grotewiel, M.S.; Martin, I.; Bhandari, P.; Cook-Wiens, E. Functional senescence in Drosophila melanogaster. Ageing Res. Rev. 2005,
4, 372–397. [CrossRef]
52. Wang, A.; Mouser, J.; Pitt, J.; Promislow, D.; Kaeberlein, M. Rapamycin enhances survival in a Drosophila model of mitochondrial
disease. Oncotarget 2016, 7, 80131–80139. [CrossRef]
53. Harrison, B.; Tran, T.T.; Taylor, D.; Lee, S.D.; Min, K.J. Effect of rapamycin on lifespan in Drosophila. Geriatr. Gerontol. Int. 2010,
10, 110–112. [CrossRef] [PubMed]
54. Cuesta, E.V.; Fan, F.; Rand, D.M. Rapamycin reduces Drosophila longevity under low nutrition. IOSR J. Pharm. 2014, 4, 43–51.
[CrossRef]
55. Dong, X.; Milholland, B.; Vijg, J. Evidence for a limit to human lifespan. Nature 2016, 538, 257–259. [CrossRef]
56. Chandler, J.A.; Innocent, L.V.; Huang, I.L.; Yang, J.L.; Eisen, B.M.; Ludington, W.B. Chronic ethanol ingestion impairs Drosophila
melanogaster health in a microbiome-dependent manner. BioRxiv 2018, 1–23. [CrossRef]
57. Ivanov, D.K.; Escott-Price, V.; Ziehm, M.; Magwire, M.M.; Mackay, T.F.C.; Partridge, L.; Thornton, J.M. Longevity GWAS using
the Drosophila Genetic Reference Panel. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 2015, 70, 1470–1478. [CrossRef] [PubMed]
58. Huang, W.; Campbell, T.; Carbone, M.A.; Jones, W.E.; Unselt, D.; Anholt, R.R.H.; Mackay, T.F.C. Context-dependent genetic
architecture of Drosophila life span. PLoS Biol. 2020, 18, 1–25. [CrossRef]
59. McKenzie, J.A.; McKechnie, S.W. A comparative study of resource utilization in natural populations of Drosophila melanogaster
and D. simulans. Oecologia 1979, 40, 299–309. [CrossRef] [PubMed]
60. Kristensen, T.N.; Loeschcke, V.; Bilde, T.; Hoffmann, A.A.; Sgró, C.; Noreikiene, K.; Ondrésik, M.; Bechsgaard, J.S. No inbreeding
depression for low temperature developmental acclimation across multiple Drosophila species. Evolution 2011, 65, 3195–3201.
[CrossRef]
61. McLaren, W.; Gil, L.; Hunt, S.E.; Riat, H.S.; Ritchie, G.R.S.; Thormann, A.; Flicek, P.; Cunningham, F. The Ensembl Variant Effect
Predictor. Genome Biol. 2016, 17, 1–14. [CrossRef]
62. Highfill, C.A.; Baker, B.M.; Stevens, S.D.; Anholt, R.R.H.; Mackay, T.F.C. Genetics of cocaine and methamphetamine consumption
and preference in Drosophila melanogaster. PLoS Genet. 2019, 15, 1–24. [CrossRef]
63. Baker, B.M.; Carbone, M.A.; Huang, W.; Anholt, R.R.H.; Mackay, T.F.C. Genetic basis of variation in cocaine and methamphetamine
consumption in outbred populations of Drosophila melanogaster. BioRxiv Prepr. 2021. [CrossRef]
